Document Detail

The effect of EGFR-related tyrosine kinase activity inhibition on the growth and invasion mechanisms of prostate carcinoma cell lines.
MedLine Citation:
PMID:  12841683     Owner:  NLM     Status:  MEDLINE    
Increased urokinase plasminogen activator (uPA) levels and epidermal growth factor receptor (EGFR)-related tyrosine kinase activity are associated with poor prognosis in several cancers. We studied the effect of epidermal growth factor (EGF) and a specific inhibitor of EGFR, ZM252868, on the growth and invasiveness of the prostate cancer cell lines PC3 and DU145. PC3 cell growth was stimulated by exogenous EGF but DU145 cell growth was not. EGFR-specific tyrosine kinase inhibitor significantly inhibited the growth of both cell types. EGF increased uPA protein level and uPA activity in both cell types. EGF stimulation also resulted in increased uPAR transcript in both cell lines. uPA production and activity were suppressed by the inhibitor to well below the levels in control cells. Matrigel invasion of PC3 cells was increased by EGF. ZM252868 also reversed the EGF-stimulated matrigel invasion by PC3 cells. Our results indicate that EGF is a potent stimulative agent for both growth and invasion in prostate cancer cells, and that targeting the EGFR function inhibits not only tumor growth but also invasiveness.
A Unlü; R E Leake
Related Documents :
10966743 - 4-anilino-6,7-dialkoxyquinoline-3-carbonitrile inhibitors of epidermal growth factor re...
11157073 - A novel role for protein tyrosine phosphatase shp1 in controlling glial activation in t...
12473383 - Modulation by caspases of tumor necrosis factor-stimulated c-jun n-terminal kinase acti...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  The International journal of biological markers     Volume:  18     ISSN:  0393-6155     ISO Abbreviation:  Int. J. Biol. Markers     Publication Date:    2003 Apr-Jun
Date Detail:
Created Date:  2003-07-04     Completed Date:  2003-08-12     Revised Date:  2009-11-19    
Medline Journal Info:
Nlm Unique ID:  8712411     Medline TA:  Int J Biol Markers     Country:  Italy    
Other Details:
Languages:  eng     Pagination:  139-46     Citation Subset:  IM    
Department of Biochemistry, Faculty of Medicine, University of Mersin, Mersin, Turkey.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Cell Division
Drug Combinations
Epidermal Growth Factor / pharmacology
Neoplasm Invasiveness
Plasminogen Activators / analysis,  genetics
Prostatic Neoplasms / pathology*
Quinazolines / pharmacology
RNA, Messenger / analysis
Receptor, Epidermal Growth Factor / antagonists & inhibitors,  physiology*
Tumor Cells, Cultured
Urokinase-Type Plasminogen Activator / analysis
Reg. No./Substance:
0/Drug Combinations; 0/Laminin; 0/Proteoglycans; 0/Quinazolines; 0/RNA, Messenger; 0/ZM 252868; 119978-18-6/matrigel; 62229-50-9/Epidermal Growth Factor; 9007-34-5/Collagen; EC, Epidermal Growth Factor; EC 3.4.21.-/Plasminogen Activators; EC Plasminogen Activator

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  CD44v10: an antimetastatic membrane glycoprotein for pancreatic cancer.
Next Document:  Transforming growth factor beta1 stimulates urokinase plasminogen activator system on prostate cance...